Overview

Nasal Protollin in Early Symptomatic Alzheimer's Disease

Status:
COMPLETED
Trial end date:
2023-02-21
Target enrollment:
Participant gender:
Summary
In this research study investigators aim to learn more about a new drug called Protollin as a possible new treatment for Alzheimer's Disease (AD). The primary goal is to assess the safety and tolerability.
Phase:
PHASE1
Details
Lead Sponsor:
Brigham and Women's Hospital
Collaborator:
I-Mab Biopharma US Limited
Treatments:
Protollin